As today’s fusion company, we're deploying and scaling fusion technology now that we hope will one day lead to powering the world. Each step of the way, we're mastering more immediate applications of fusion – like inspecting industrial components through neutron imaging and producing cancer-fighting medicine. These applications create tremendous social and economic value and are the building blocks for our future goals: recycling nuclear waste and generating on-demand, carbon-free energy through fusion.
We've designed our four-phased approach to produce meaningful outcomes at each stage as we work toward fusion energy. As proud as we are of what we have accomplished already, we are even more excited about what's to come.
Veendam, the Netherlands is home to our European medical isotope production efforts. SHINE Europe will enhance our mission to bolster the nuclear medicine supply chain across the globe. Near-term, European efforts will focus on addressing urgent needs for therapeutic isotopes like lutetium-177. SHINE Europe has also been working since 2019 on plans for a production facility for diagnostic isotopes, like molybdenum-99, that would replicate the layout and production capacity of our Chrysalis facility. Additionally, in 2022, SHINE Europe announced the Dutch government approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.
Developing revolutionary fusion technology throughout each of our four phases.
Future generations will look back on the development of fusion technologies as a turning point in human history. We believe fusion will profoundly change the kinds of problems we can solve, elevate standards of living for all people, and achieve an unprecedented level of environmental harmony. Join our team and help us redefine what's possible.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.